Compositions and methods for enhancing contrast in imaging
Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.
1. A composition for enhancing contrast of one or more areas of a subject for X-ray imaging when administered to the subject, the composition comprising:
liposomes, the liposomes encapsulating one or more iodinated nonradioactive contrast-enhancing agents, and the liposomes comprising: cholesterol, at least one phospholipid, and at least one phospholipid which is derivatized with a polymer chain,
wherein the average diameter of the liposomes is less than 150 nanometers.
2. The composition of claim 1 , wherein the X-ray imaging is computed tomography.
3. The composition of claim 1 , wherein the iodinated nonradioactive contrast-enhancing agents are selected from at least one of: iodinated ionic compounds, iodinated nonionic compounds, and mixtures thereof.
4. The composition of claim 3 , wherein a suspension of the liposomes has a concentration of at least 30 milligrams of iodine per milliliter of the suspension.
5. The composition of claim 1 , wherein the average diameter of the liposomes is less than 120 nanometers.
6. The composition of claim 1 , wherein the composition is capable of being administered to the bloodstream of the subject.
7. The composition of claim 6 , wherein the composition provides an enhanced contrast that remains detectable at least 30 minutes after administration.
8. The composition of claim 6 , wherein the composition provides an enhanced contrast of at least 50 Hounsfield units in at least part of at least one of a vasculature and an organ of the subject.
9. The composition of claim 1 , wherein the liposomes are PEGylated liposomes.
10. The composition of claim 1 , wherein the liposomes are targeted liposomes.
11. A composition for enhancing contrast of one or more areas of a subject for X-ray imaging when administered to the subject, the composition comprising liposomes, the liposomes comprising:
at least one first lipid or phospholipid;
at least one second lipid or phospholipid which is derivatized with one or more polymers; and
at least one sterically bulky excipient capable of stabilizing the liposomes;
wherein the average diameter of the liposomes is less than 150 nanometers, and wherein the liposomes encapsulate at least one iodinated nonradioactive contrast enhancing agent.
12. The composition of claim 11 , wherein the at least one first lipid or phospholipid comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC).
13. The composition of claim 11 , wherein the at least one second lipid or phospholipid which is derivatized with one or more polymers comprises N-carbamylmethoxypoly(ethylene glycol)-1,2-distearoyl-sn-glycerol-3-phosphoethanolamine (DSPL-MPLG2000).
14. The composition of claim 11 , wherein the at least one sterically bulky excipient is selected from at least one of: sterols, fatty alcohols, fatty acids, and mixtures thereof.
15. The composition of claim 11 , wherein the at least one sterically bulky excipient is cholesterol.
16. The composition of claim 11 , wherein the liposomes are not autoclaved.
17. The composition of claim 11 , wherein the liposomes are contained in a suspension medium, at least some of the iodinated nonradioactive contrast enhancing agent that has not been encapsulated by the liposomes having been removed from the suspension medium.
18. The composition of claim 11 , wherein the at least one first lipid or phospholipid is present in the amount of about 55 to about 75 mol %; the at least one second lipid or phospholipid which is derivatized with one or more polymers is present in the amount of about 1 to about 20 mol %; and the at least one sterically bulky excipient is present in the amount of about 25 to about 40 mol %.
19. The composition of claim 18 , wherein the at least one first lipid or phospholipid is hydrogenated soy phosphatidylcholine; the at least one second lipid or phospholipid which is derivatized with one or more polymers is N-carbamylmethoxypoly(ethylene glycol)-1,2-distearoyl-sn-glycerol-3-phosphoethanolamine (DSPL-MPLG2000); and the at least one sterically bulky excipient is cholesterol.